Replimune (REPL) Preferred Stock Liabilities (2018)
Replimune (REPL) posted Preferred Stock Liabilities of $86.4 million for Q2 2018, little changed sequentially from $86.4 million in Q1 2018.
Powered by 
Analysis
Replimune (REPL) Preferred Stock Liabilities (2018) Analysis & Trends
Replimune has reported Preferred Stock Liabilities for 1 years, with the latest figure at $86.4 million in Q2 2018.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $86.4 million in Q2 2018, while the trailing twelve-month figure through Jun 2018 was $86.4 million (changed N/A YoY) and the FY2018 annual result came in at $86.4 million, changed N/A from the prior year.
- Preferred Stock Liabilities was little changed at $86.4 million in Q2 2018 per REPL's latest filing, from $86.4 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $86.4 million in Q1 2018 and troughed at $86.4 million in Q1 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Replimune | 1.46 Bn | 1.46 Bn | - | - |